Novel missense variants associated with GNE myopathy

Johanna Ranta-aho[1,2*], Viviana Cetrangolo[1,3*], Luca Bello[4], Giuliana Capece[4], Elena Pegoraro[4], Maria Francesca Di Feo[1,2,5], Violeta Mihaylova[6], Hans H. Jung[7], Fabien Hauw[8], Tanya Stojkovic[8], Anthony Behin[8], Norma Romero[8], Thierry Maisonobe[8], Matteo Lucchini[9,10], Miguel Oliveira Santos[11], Massimiliano Mirabella[9,10], Giorgio Tasca[12], Marco Savarese[1,2], Bjarne Udd[13]* and Mridul Johari[14]*

*Contributed equally to this study

1. Folkhälsan Research Center, Haartmaninkatu 8, 00290, Helsinki, Finland
2. Department of Medical Genetics, Medicum, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland
3. Telethon Institute of Genetics and Medicine-TIGEM, 80078, Pozzuoli (NA), Italy
4. Neuromuscular Unit, Department of Neurosciences DNS, University of Padova, via Giustiniani, 5, 35128, Padova, Italy
5. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (DINOGMI), University of Genoa, Genova, Italy
6. Neurocenter, University teaching and research hospital Lucerne, Lucerne, Switzerland
7. Department of Neurology, University Hospital Zürich, Zürich, Switzerland
8. Centre de référence des maladies neuromusculaires Nord/Est/Ile de France , Hôpital Pitié-Salpêtrière, 75013
9. Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
10. UOC Neurologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
11. Neurosciences and Mental Health, ULS Hospital de Santa Maria. Institute of Physiology and Centro de Estudos Egas Moniz. Faculty of Medicine, University of Lisbon, Lisbon, Portugal
12. John Walton Muscular Dystrophy Research Centre, NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
13. Tampere Neuromuscular Center, Tampere University and Tampere University Hospital, Biokatu 8, 33530, Tampere, Finland
14. Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, WA, Australia

Corresponding author:
Mridul Johari
Email: mridul.johari@uwa.edu.au
Full address:
Harry Perkins Institute of Medical Research
6 Verdun St,
Nedlands, WA, 6009, Australia

Abstract

GNE myopathy is a rare autosomal recessive skeletal muscle disorder characterized by progressive distal muscle weakness, typically starting in the lower legs and gradually involving proximal muscle groups. It is an autosomal recessive disease, caused by biallelic variants in *GNE*. To date, over 350 causative *GNE* variants have been reported, however, establishing genotype-phenotype correlation remains difficult due to clinical heterogeneity and limited patient numbers. In this study, we describe 20 unrelated European families with a diagnosis of GNE myopathy and biallelic *GNE* variants identified in either homozygosity or compound heterozygosity. While the majority of variants observed in our cohort have been previously reported, we identified five novel missense variants: p.(G355R), p.(A679T), p.(I709T), p.(V727G), and p.(V744I). Using *in silico* prediction tools and ACMG/AMP criteria, we classified p.(G355R) and p.(V727G) as likely pathogenic. The clinical features of our cohort were consistent with the classical presentation of GNE myopathy. Our findings contribute new genotype data and support ongoing efforts to refine variant interpretation in GNE myopathy. This study expands the mutational spectrum of *GNE* and reinforces the phenotypic consistency across diverse populations.

1 Introduction

Biallelic variants in the *GNE* gene, which encodes UDP-N-Acetylglucosamine 2-epimerase/N-Acetylmannosamine Kinase, cause an autosomal recessive GNE myopathy (GNEM), characterized by progressive muscle weakness, initially affecting the distal muscles of the lower limbs and gradually involving the hamstrings and other muscle groups over time [1, 2].

The *GNE* gene located on chromosome 9, consists of 13 exons and encodes for two major protein coding isoforms. The hGNE1 (NM_005476.7/ENST00000642385.2) transcript encodes for 722 amino acids (NP_005467) and is the MANE Select transcrtipt for *GNE*. The longer hGNE2 (NM_001128227.3/ENST00000396594.8), on the other hand, encodes for 753 amino acids (NP_001121699) is designated as MANE Plus Clinical and commonly used for variant annotation [3].

To date, over 350 causative *GNE* variants have been reported [4]. These are predominantly missense variants, but insertions, deletions, nonsense, intronic, and splice site variants have also been identified. However, there are no recorded cases of GNEM patients with two null variants, and knock-out animal models have shown larval mortality, suggesting that the absence of *GNE* is lethal [5-7].

Globally, GNEM has an estimated worldwide incidence of 1 to 9 individuals per million (Orphanet; https://www.orpha.net) [4]. However, the prevalence varies across different populations due to founder effects and is likely still underestimated in some populations. Most *GNE* variants are unique to a single family, however, several founder variants in specific populations have been identified [8-12]. Most notably, these populations include the Middle Eastern (p.(M743T)), the Japanese (p.(C44S), p.(D207V), p.(V603L)), the Roma Bulgarian (p.(I618T)), and the Indian/Asian (p.(A662V), p.(V727M)) [9, 12-14].

Clinically, the typical first symptom of GNEM is the weakness of the anterior tibialis muscle, and consequent foot drop and gait disturbance [15-17]. This usually occurs in early adulthood [18]. As the disease progresses, the weakness slowly spreads to proximal muscles and upper extremities [5].

A unique feature of GNEM is the relatively spared quadriceps muscles despite the involvement of other muscles of the lower extremities [19]. The quadriceps sparing

is a useful diagnostic feature, as it is hardly found in other neuromuscular disorders [20]. Typical histopathological findings from muscle biopsies of GNEM patients include fiber size variation and atrophic muscle fibers with rimmed vacuoles that relate to autophagosomal abnormality. Accumulation of phosphorylated TDP-43, p62 and beta-amyloid are also commonly found in myofibers of the patients [21]. Despite the characteristic features of GNEM, diagnosis is best established through a combination of clinical assessment, muscle imaging, and confirmatory genetic testing to identify pathogenic variants in both alleles [22-24]. Muscle biopsy is not routinely necessary anymore and is typically reserved for selected cases where the diagnosis remains unclear after initial evaluation.

While the addition of *GNE* in neuromuscular gene panels has eased the diagnosis of GNEM, establishing genotype-phenotype correlation remains challenging. This is partially due to significant variability of the disease phenotype and a relatively low number of patients [25]. The better established genotype-phenotype correlations include the predisposition to a milder phenotype associated with the variant p.(D207V) [26], and an earlier onset associated with p.(L539S) [27]. Phenotypic differences between homozygous patients and compound heterozygous patients have also been reported; patients with p.(V603L) in homozygosity tend to experience a more severe disease than patients with the same variant in compound heterozygosity [27]. The location of the variants with respect to the protein domains of GNE may also play a role in the observed phenotype: patients with variants in both enzymatic domains are more likely to have earlier disease onset and become non-ambulant, in comparison to patients who have both of their variants within the same domain [5, 28]. Despite these genotype-phenotype correlations, the genotype can only partially explain phenotypic variability, as significant inter- and intrafamilial variability is present in GNEM [12].

The genotypic and phenotypic diversity is also paralleled by the wide variety of proposed pathomechanisms underlying GNEM. Historically, sialic acid deficiency and consequent decreased sialylation of muscle glycoproteins has been widely accepted as the main pathomechanism associated with variants in *GNE*. However, recently, more research has emerged on the cellular processes related to *GN*E, suggesting that GNE expression can affect cytoskeletal organization, oxidative stress, endoplasmic reticulum stress, myogenesis, and muscle regeneration independently from hyposialylation [25].

In light of the expanding genotypic spectrum of *GNE* myopathy and growing insights into its diverse pathomechanisms, here we report 20 families from Europe where the patients are affected by GNEM and carry *GNE* variants in homozygosity or compound heterozygosity. Most of the variants in our cohort are previously reported in literature, but we also present five novel, previously unreported variants, expanding the genotypic and phenotypic spectrum of GNEM.

2 Methods

2.1 Patients and clinical examinations

We collected deep phenotyping data from 20 individuals. Diagnostic material was obtained by the referring clinicians with informed consent from the patients or their legal guardians. The study was performed according to the Declaration of Helsinki, and ethical permission was obtained through the institutional review board of University of Helsinki and Helsinki University Hospital, Helsinki, Finland (HUS:195/13/03/00/11). Muscle imaging data, electrophysiological examination results (nerve conduction studies and needle electromyogram, EMG), creatine kinase (CK) measurements and cardiac function test results were obtained for most patients (Table 1). Myo-MRI and cardiac assessments were conducted in 16 patients.

2.2 Molecular genetic analysis

All variants were detected by high-throughput sequencing (short read-exome or targeted gene panel) of genomic DNA obtained from the blood samples of affected individuals and confirmed by Sanger sequencing. All variants are reported using the MANE Plus Clinical transcript NM_001128227.3 (hGNE2). Pathogenicity classification of the variants was performed according to the guidelines by the American College of Medical Genetics and Genomics (ACMG) and the Association of for Clinical and Genomic Science (ACGS) [29, 30]. SpliceAI was used for predicting effects of these variants on mRNA splicing. Minor allele frequencies (MAF) were obtained from the GnomAD database (version 4.1.0). AlphaMissense and AlphaFold prediction tools were also used to predict the protein structure and the variant pathogenicity [31-33].

3 Results

3.1 Clinical features

The clinical features of the 20 patients present in our cohort are summarized in Table 1. Patients 14, 15, and 16 were previously reported in an Italian cohort by Bortolani et al [34]. A positive family history was reported in 50% of the patients (10/20). A minority of the patients (15%, 3/20) had consanguineous parents. All patients were followed for several years, ranging from 4-75 years, with a mean follow-up duration of approximately 20 years. The mean age at onset was 29 years, ranging from 18-50 years. The mean age at the last clinical evaluation was 50 years. Overall, most of the patients presented with muscle weakness beginning in the distal lower limbs, typically initially presenting as foot drop and weakness of the anterior tibialis. Over the course of the disease, the muscle weakness progressed to proximal lower limbs and later to the upper limbs. Within the cohort, ~22% of the patients (4/18) had lost ambulation (Table 1), with an average time to loss of ambulation of approximately 9 years from symptom onset. Some patients also showed paravertebral (9/20), neck (11/20), and facial weakness (6/20). Out of 16 patients with myo-MRI data, only two patients had a mildly affected quadriceps, while in 14 patients it was spared. Anterior leg and posterior thigh muscles were the most severely affected. Figure 1 shows myo-MRI of thighs and legs of patient number 20 (Table 1) with a very advanced stage of disease. Autophagic rimmed vacuoles were detected in 14/17 patients who underwent muscle biopsy. Respiratory involvement was evaluated in 15 patients by forced vital capacity (FVC). It was preserved or only mildly reduced in all but two cases: one patient had a moderate restrictive ventilatory defect, and another showed a severe, but not further specified reduction in FVC. Four patients, aged between 19 and 42 years, also had unspecific cardiovascular symptoms, such as mild aortic and mitral insufficiency, hypertrophic cardiomyopathy, and hypertensive cardiomyopathy (together with type 2 diabetes, found in patient 20 at the age range of 15-20).

3.2 Genetics

Twenty patients from unrelated families were included in our cohort (Table 2). Fourteen patients were of European origin, one of them carrying the p.(M743T) founder variant and two of them the p.(I618T) founder variant in homozygosity. Two patients, one with parents originating from Bangladesh and the other with Comorian ancestry, carried the Indian/Asian p.(V727M) variant in compound heterozygosity with another missense variant. Altogether, in our cohort, we found 23 different *GNE* variants, including five novel, previously unreported variants. These novel variants

were p.(G355R), p.(A679T), p.(I709T), p.(V727G), and p.(V744I). Seven patients carried variants in homozygosity, while 13 patients were compound heterozygous. The majority of the reported variants were missense, but three different heterozygous nonsense variants were also identified. The missense variants were evenly distributed across the protein structure: eight variants were located in the UDP-GlcNAc-Epimerase domain, while 12 were in the ManNAc Kinase domain. Most of the variants were rare in the general population, with a maximum frequency of less than 1 in 10,000 in the gnomAD database (version 4.1.0). The only exception were the variants p.(V727M) and p.(M743T), seen in higher frequencies (0.01241 in South Asian population, and 0.0026 in Middle Eastern population, respectively). SpliceAI scored almost all the variants lower than 0.1, and thus, they are not predicted to affect splicing. The notable exception was p.(A631V) with a SpliceAI score of 0.97.

3.3 AlphaMissense and AlphaFold prediction

Missense variants can often lead to problems in protein folding or affect protein activity or stability. To investigate the impact of the novel missense variants identified in our study, we used AlphaMissense, a machine learning tool developed by DeepMind, widely used for predicting the pathogenicity of missense variants [31]. AlphaMissense predicted five variants as pathogenic (score of 0.57 or higher), 14 variants as uncertain significance (VUS), and four variants as benign. In accordance with the recent ClinGen PP3 criterion recommendations [35], the variants p.(G355R) and p.(V272G) were assigned supporting evidence of pathogenicity (PP3_Supporting, +1), based on their AlphaMissense scores of 0.87 and 0.80, respectively. In contrast, the variants—p.(A679T) and p.(V744I)—did not meet the threshold of PP3 criterion, with scores of 0.50 and 0.25. Additionally, the variant p.(I709T), with an AlphaMissense score of 0.08, also did not reach sufficient evidence for PP3 criterion (Table 3).

Furthermore, to generate and visualize the structural changes of wild-type and mutated proteins, we run AlphaFold2 [32](Figure 2). None of the novel missense variants predicted with AlphaFold2 showed a severe impact on the protein folding. However, given the structural context and the different biochemical proprieties of the mutated amino acids, these changes may still exert a pathogenic effect–possibly by impairing protein function and interactions rather than folding.

3.4 Pathogenicity classification

We classified the *GNE* variants in our cohort by predicted pathogenicity, according to the ACMG and the ACGS guidelines [29, 30]. All previously reported variants reached a classification of “pathogenic” or “likely pathogenic”, largely based on previous literature, along with additional evidence based on our cohort. As the patients in our cohort present with a phenotype compatible with GNEM, and genetically, their *GNE* variants are observed in *trans*, we were able to add PP4_Supporting and PM3_Supporting criteria, strengthening the evidence of pathogenicity.

Similarly, we applied ACMG and ACGS guidelines to the novel *GNE* variants identified in our cohort to establish variant classification (Table 3). The variants p.(G355R) and p.(V727G) reached “likely pathogenic”, based on the observed phenotype, the low frequency of the variants, computational evidence, and location in a mutational hotspot within either the UDP-GlcNAc 2-Epimerase or the ManNac Kinase domain. The variant p.(G355R) gained additional evidence from being detected *in trans* with a pathogenic variant (PM3_Moderate +2). Finally, both variants cause a substitution of an amino acid residue where a different one has been determined to be pathogenic. Thus, PM5_Supporting was applied to p.(G355R), while PM5_Moderate was applied to p.(V727G), as there is extensive evidence supporting the pathogenicity of the variant p.(V727M) in literature [3, 5, 8, 13, 36-48]. In contrast, the novel variants p.(A679T), p.(I709T) and p.(V744I) did not garner enough evidence to reach a classification of “pathogenic” or “likely pathogenic”, and thus, were classified as VUS.

4 Discussion

We report a large cohort of GNEM patients, collectively carrying 23 different variants in *GNE*. The clinical data from this cohort are highly consistent with the characteristic features of GNEM, including distal myopathy initially affecting the lower limbs, with gradual progression to proximal and upper limb muscles, relative sparing of the quadriceps, and the presence of rimmed vacuoles on muscle histopathology. In our cohort, the proportion of patients with respiratory involvement was low, comparable to that reported in a recent Italian cohort [34]. Conversely, the proportion of patients who had lost ambulation was strikingly high, also mirroring the findings of Bortolani et al.

A few of our patients presented with comorbidities and multisystemic symptoms, including cardiovascular disease and diabetes, even at a young age. Four

patients presented with a variety of cardiac symptoms, including aortic and mitral insufficiency, repolarization issues, and hypertrophic cardiomyopathy. While clear association between *GNE* variants and cardiac abnormalities has not been established [49, 50], GNEM patients present with cardiac involvement including arrythmia, valvular defects and hypertrophic cardiomyopathy at a higher frequency than the general population [50]. Interestingly, the GNEM phenotype is strikingly similar to *ACTN2*-related late-onset distal myopathy, which also begins with foot drop caused by the weakness of the tibialis muscle. However, *ACTN2* also has a long-standing association with cardiomyopathy [51]. Further, from a functional point of view, *ACTN2* and *GNE* directly interact with each other, and *GNE* variants have been shown to alter this interaction [52], which, together with the similar associated skeletal muscle phenotype, may suggest a shared disease etiology. Thus, it cannot be excluded that some of the younger patients in our cohort may develop cardiac symptoms over time. At the same time, we cannot rule out the contribution of variants in other genes to the cardiac phenotype. Similarly, studies investigating non-muscle-related comorbidities in patients with *GNE* mutations remain limited, and thus, their relation to the identified *GNE* variants is difficult to assess.

Out of the 23 *GNE* variants presented in our cohort, five were novel, previously unreported variants. Yet, three of these novel variants cause a substitution of an amino acid residue where a variant causing a different amino acid change in the same position has already been reported in literature. In particular, p.(V727M) has widely been associated GNEM, supporting the pathogenicity of p.(V727G) in our cohort [3, 5, 8, 13, 36-48]. There are also a few reports that support the pathogenicity of variants causing an amino acid change in the same positions as p.(G355R) and p.(A679T) [53-55], however, the evidence is considerably weaker compared to p.(V727M). On the other hand, in our cohort, p.(G355R) is observed *in trans* with a null variant p.(R27*), which significantly supports its pathogenicity, and p.(A679T) is observed in homozygosity.

While recent evidence supports the pathogenicity of the novel variants p.(A679T), p.(I709T) and p.(V744I), this evidence is not robust enough to reach the formal “pathogenic” or “likely pathogenic” in ACMG classification. To further support the pathogenicity of these novel missense variants, we exploited the AlphaMissense AI tool. The scores from this tool corroborate the ACMG pathogenicity classification, except for p.(I709T), highlighting the functional impact of these variants and thus

strengthening the evidence for their pathogenicity associated with GNEM phenotype of our patients. One of the AlphaMissense criteria for the pathogenicity is the structural context of a variant. Thus, depending on the location of the amino acid within the protein, the variant can affect the function of the protein. The variant p.(A679T) is classified as VUS, however, its AlphaMissense score of 0.533, its location in the functional kinase domain and in an amino acid residue where other substitutions have previously been reported as pathogenic clearly point towards pathogenicity. Conversely, the variant p.(V744I), also classified as uncertain, has a relatively low score of 0.244, decreasing its association with strong pathogenicity evidence. Finally, the considerably low score (0.08) of p.(I709T) and its subsequent classification as likely benign by AlphaMissense is probably linked to the structural location of the variant. This variant is indeed located in a structural context almost entirely classified as benign by AlphaMissense, suggesting that variants in this domain do not have a high functional impact. Nevertheless, we infer that the combination *in trans* of p.(I709T) and the pathogenic variant p.(V696M) can be associated with the GNEM phenotype we observed.

5 Conclusion

Overall, our results expand the genotypic and phenotypic spectrum of GNEM. Clinically, our cohort is highly consistent with previous reports of GNEM patients. A few of our patients present with comorbidities and multisystemic symptoms, including diabetes and cardiovascular disease, at a young age. Further studies, including natural history studies and patient registries will be essential to clarify the potential multisystemic impact of pathogenic *GNE* variants. Further evidence is also needed to clarify the potential impact of the three variants reported here, which were classified as VUS. This highlights how, despite significant advances in *in silico* tools for missense variant pathogenicity prediction, the sharing of clinical cases among clinicians and researchers still plays a pivotal role in gathering sufficient evidence for robust pathogenicity classification.

Acknowledgements

The authors would like to thank the patients and their families for cooperation in this study. Computational resources were provided by CSC – IT Center for Science, Finland.

Funding

MJ is supported by the Association Française contre les Myopathies (AFM Téléthon, The French Muscular Dystrophy Association, grant award number: 24438). M.S. received fundings from the European Union (Grant Agreement 101080844 to CoMPaSS-NMD), Academy of Finland (grant 339434, 346209, 361979), Association Française contre les Myopathies (grant 23281), Sigrid Juselius Foundation (230217), and Samfundet Folkhälsan i Svenska Finland. GT is supported by the Academy of Medical Sciences Professorship Scheme (Grant APR8\1017). BU is supported by the Sigrid Jusélius Foundation.

Competing interests

The authors disclose no conflicts of interest.

Data statement

All relevant clinical and genetic data has been shared in the manuscript. Any additional de-identified data can be made available on reasonable request, subject to appropriate data sharing agreements and ethical guidelines.

Author contributions

Conceptualisation of the study: MJ, BU, MS

Project administration: MJ, BU, MS

Funding acquisition: MJ, BU, MS

Supervision: MJ, BU, MS

Patient samples and data collection: GC, EP, MFDF, VM, HJ, TS, AB, NR, TM, ML, MOS, MM, GT and BU

Data analysis and curation: JRA, VC, MFDF, MJ

Methodology: JRA, VC, MFDF, MS, MJ

Visualisation: JRA, VC

Writing the original draft: JRA, VC

Review and editing of the manuscript: all co-authors

References

[1] Nonaka I, Sunohara N, Ishiura S, Satoyoshi E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. J Neurol Sci 1981;51(1):141-55. https://doi.org/10.1016/0022-510x(81)90067-8

[2] Argov Z, Yarom R. "Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews. J Neurol Sci 1984;64(1):33-43. https://doi.org/10.1016/0022-510x(84)90053-4

[3] Huizing M, Carrillo-Carrasco N, Malicdan MC, Noguchi S, Gahl WA, Mitrani-Rosenbaum S, et al. GNE myopathy: new name and new mutation nomenclature. Neuromuscul Disord 2014;24(5):387-9. https://doi.org/10.1016/j.nmd.2014.03.004

[4] Derksen A, Thompson R, Shaikh M, Spendiff S, Perkins TJ, Lochmuller H. Estimating the Prevalence of GNE Myopathy Using Population Genetic Databases. Hum Mutat 2024;2024(7377504. https://doi.org/10.1155/2024/7377504

[5] Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion. Neuromuscul Disord 2018;28(2):158-168. https://doi.org/10.1016/j.nmd.2017.11.001

[6] Schwarzkopf M, Knobeloch KP, Rohde E, Hinderlich S, Wiechens N, Lucka L, et al. Sialylation is essential for early development in mice. Proc Natl Acad Sci U S A 2002;99(8):5267-70. https://doi.org/10.1073/pnas.072066199

[7] Livne H, Avital T, Ruppo S, Harazi A, Mitrani-Rosenbaum S, Daya A. Generation and characterization of a novel gne Knockout Model in Zebrafish. Front Cell Dev Biol 2022;10(976111. https://doi.org/10.3389/fcell.2022.976111

[8] Chaouch A, Brennan KM, Hudson J, Longman C, McConville J, Morrison PJ, et al. Two recurrent mutations are associated with GNE myopathy in the North of Britain. J Neurol Neurosurg Psychiatry 2014;85(12):1359-65. https://doi.org/10.1136/jnnp-2013-306314

[9] Argov Z, Eisenberg I, Grabov-Nardini G, Sadeh M, Wirguin I, Soffer D, et al. Hereditary inclusion body myopathy: the Middle Eastern genetic cluster. Neurology 2003;60(9):1519-23. https://doi.org/10.1212/01.wnl.0000061617.71839.42

[10] Zhao J, Wang Z, Hong D, Lv H, Zhang W, Chen J, et al. Mutational spectrum and clinical features in 35 unrelated mainland Chinese patients with GNE myopathy. J Neurol Sci 2015;354(1-2):21-6. https://doi.org/10.1016/j.jns.2015.04.028

[11] Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, Oya Y, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 2002;59(11):1689-93. https://doi.org/10.1212/01.wnl.0000041631.28557.c6

[12] Chamova T, Guergueltcheva V, Gospodinova M, Krause S, Cirak S, Kaprelyan A, et al. GNE myopathy in Roma patients homozygous for the p.I618T founder mutation. Neuromuscul Disord 2015;25(9):713-8. https://doi.org/10.1016/j.nmd.2015.07.004

[13] Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29(1):83-7. https://doi.org/10.1038/ng718

[14] Tomimitsu H, Shimizu J, Ishikawa K, Ohkoshi N, Kanazawa I, Mizusawa H. Distal myopathy with rimmed vacuoles (DMRV): new GNE mutations and splice variant. Neurology 2004;62(9):1607-10. https://doi.org/10.1212/01.wnl.0000123115.23652.6c

[15] Argov Z, Bronstein F, Esposito A, Feinsod-Meiri Y, Florence JM, Fowler E, et al. Characterization of Strength and Function in Ambulatory Adults With GNE Myopathy. J Clin Neuromuscul Dis 2017;19(1):19-26. https://doi.org/10.1097/CND.0000000000000181

[16] Park YE, Kim DS, Choi YC, Shin JH. Progression of GNE Myopathy Based on the Patient-Reported Outcome. J Clin Neurol 2019;15(3):275-284. https://doi.org/10.3988/jcn.2019.15.3.275

[17] Murtazina A, Nikitin S, Rudenskaya G, Sharkova I, Borovikov A, Sparber P, et al. Genetic and Clinical Spectrum of GNE Myopathy in Russia. Genes (Basel) 2022;13(11). https://doi.org/10.3390/genes13111991

[18] Argov Z. GNE myopathy: a personal trip from bedside observation to therapeutic trials. Acta Myol 2014;33(2):107-10.

[19] Mayhew J, Bonner N, Arbuckle R, Turnbull A, Bowden A, Skrinar A. Development and preliminary evidence of the psychometric properties of the GNE myopathy functional activity scale. J Comp Eff Res 2018;7(4):381-395. https://doi.org/10.2217/cer-2017-0062

[20] Chan YM, Lee P, Jungles S, Morris G, Cadaoas J, Skrinar A, et al. Substantial deficiency of free sialic acid in muscles of patients with GNE myopathy and in a mouse model. PLoS One 2017;12(3):e0173261. https://doi.org/10.1371/journal.pone.0173261

[21] Li H, Chen Q, Liu F, Zhang X, Li W, Liu S, et al. Unfolded protein response and activated degradative pathways regulation in GNE myopathy. PLoS One 2013;8(3):e58116. https://doi.org/10.1371/journal.pone.0058116

[22] Liu CY, Yao J, Kovacs WC, Shrader JA, Joe G, Ouwerkerk R, et al. Skeletal Muscle Magnetic Resonance Biomarkers in GNE Myopathy. Neurology 2021;96(5):e798-e808. https://doi.org/10.1212/WNL.0000000000011231

[23] Fatehi F, Advani S, Okhovat AA, Ziaadini B, Shamshiri H, Nafissi S. Thigh and Leg Muscle MRI Findings in GNE Myopathy. J Neuromuscul Dis 2021;8(4):735-742. https://doi.org/10.3233/JND-210629

[24] Tasca G, Ricci E, Monforte M, Laschena F, Ottaviani P, Rodolico C, et al. Muscle imaging findings in GNE myopathy. J Neurol 2012;259(7):1358-65. https://doi.org/10.1007/s00415-011-6357-6

[25] Pereira BL, Barbosa M, Granjo P, Lochmuller H, Videira PA. Beyond sialylation: Exploring the multifaceted role of GNE in GNE myopathy. Mol Genet Metab 2025;144(4):109075. https://doi.org/10.1016/j.ymgme.2025.109075

[26] Lv XQ, Xu L, Lin PF, Yan CZ. Clinical, genetic, and pathological characterization of GNE myopathy in China. Neurol Sci 2022;43(7):4483-4491. https://doi.org/10.1007/s10072-022-05938-8

[27] Pogoryelova O, Wilson IJ, Mansbach H, Argov Z, Nishino I, Lochmuller H. GNE genotype explains 20% of phenotypic variability in GNE myopathy. Neurol Genet 2019;5(1):e308. https://doi.org/10.1212/NXG.0000000000000308

[28] Ohno K. Mutation analysis of a large cohort of GNE myopathy reveals a diverse array of GNE mutations affecting sialic acid biosynthesis. J Neurol Neurosurg Psychiatry 2014;85(8):831.
https://doi.org/10.1136/jnnp-2013-306414

[29] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405-24.
https://doi.org/10.1038/gim.2015.30

[30] Durkie M, Cassidy E, Berry I, Owens M, Turnbull C, Scott RH, et al., ACGS Best Practice Guidelines for Variant Classification in Rare DIsease 2024. 2024, Association for Clinical and Genomic Science.

[31] Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 2023;381(6664):eadg7492.
https://doi.org/10.1126/science.adg7492

[32] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596(7873):583-589.
https://doi.org/10.1038/s41586-021-03819-2

[33] Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods 2022;19(6):679-682.
https://doi.org/10.1038/s41592-022-01488-1

[34] Bortolani S, Savarese M, Vattemi G, Bonanno S, Falzone YM, Pugliese A, et al. Clinical, Histopathologic, and Genetic Features of Patients With Myofibrillary and Distal Myopathies: Experience From the Italian Network. Neurology 2024;103(4):e209697.
https://doi.org/10.1212/WNL.0000000000209697

[35] Bergquist T, Stenton SL, Nadeau EAW, Byrne AB, Greenblatt MS, Harrison SM, et al. Calibration of additional computational tools expands ClinGen recommendation options for variant classification with PP3/BP4 criteria. Genet Med 2025;27(6):101402.
https://doi.org/10.1016/j.gim.2025.101402

[36] Huizing M, Rakocevic G, Sparks SE, Mamali I, Shatunov A, Goldfarb L, et al. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab 2004;81(3):196-202.
https://doi.org/10.1016/j.ymgme.2003.11.012

[37] Liewluck T, Pho-Iam T, Limwongse C, Thongnoppakhun W, Boonyapisit K, Raksadawan N, et al. Mutation analysis of the GNE gene in distal myopathy with rimmed vacuoles (DMRV) patients in Thailand. Muscle Nerve 2006;34(6):775-8.
https://doi.org/10.1002/mus.20583

[38] Saechao C, Valles-Ayoub Y, Esfandiarifard S, Haghighatgoo A, No D, Shook S, et al. Novel GNE mutations in hereditary inclusion body myopathy patients of non-Middle Eastern descent. Genet Test Mol Biomarkers 2010;14(2):157-62.
https://doi.org/10.1089/gtmb.2009.0157

[39] Voermans NC, Guillard M, Doedee R, Lammens M, Huizing M, Padberg GW, et al. Clinical features, lectin staining, and a novel GNE frameshift mutation in hereditary inclusion body myopathy. Clin Neuropathol 2010;29(2):71-7.

[40] Boyden SE, Duncan AR, Estrella EA, Lidov HG, Mahoney LJ, Katz JS, et al. Molecular diagnosis of hereditary inclusion body myopathy by linkage analysis and identification of a novel splice site mutation in GNE. BMC Med Genet 2011;12(87.
https://doi.org/10.1186/1471-2350-12-87

[41] Nalini A, Gayathri N, Nishino I, Hayashi YK. GNE myopathy in India. Neurol India 2013;61(4):371-4.
https://doi.org/10.4103/0028-3886.117609

[42] No D, Valles-Ayoub Y, Carbajo R, Khokher Z, Sandoval L, Stein B, et al. Novel GNE mutations in autosomal recessive hereditary inclusion body myopathy patients. Genet Test Mol Biomarkers 2013;17(5):376-82.
https://doi.org/10.1089/gtmb.2012.0408
[43] Tanboon J, Rongsa K, Pithukpakorn M, Boonyapisit K, Limwongse C, Sangruchi T. A Novel Mutation of the GNE Gene in Distal Myopathy with Rimmed Vacuoles: A Case with Inflammation. Case Rep Neurol 2014;6(1):55-9.
https://doi.org/10.1159/000360730
[44] Garland J, Stephen J, Class B, Gruber A, Ciccone C, Poliak A, et al. Identification of an Alu element-mediated deletion in the promoter region of GNE in siblings with GNE myopathy. Mol Genet Genomic Med 2017;5(4):410-417.
https://doi.org/10.1002/mgg3.300
[45] Zhu W, Eto M, Mitsuhashi S, Takata K, Beck G, Sumi-Akamaru H, et al. GNE myopathy caused by a synonymous mutation leading to aberrant mRNA splicing. Neuromuscul Disord 2018;28(2):154-157.
https://doi.org/10.1016/j.nmd.2017.11.003
[46] Chakravorty S, Nallamilli BRR, Khadilkar SV, Singla MB, Bhutada A, Dastur R, et al. Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent. Front Neurol 2020;11(559327.
https://doi.org/10.3389/fneur.2020.559327
[47] Torchia E, Lucchini M, Bortolani S, Monforte M, Garibaldi M, Mirabella M, et al. Upper body involvement in GNE myopathy assessed by muscle imaging. Neuromuscul Disord 2022;32(5):410-418.
https://doi.org/10.1016/j.nmd.2021.12.007
[48] Khadilkar SV, Halani HA, Dastur R, Gaitonde PS, Oza H, Hegde M. Genetic Appraisal of Hereditary Muscle Disorders In A Cohort From Mumbai, India. J Neuromuscul Dis 2022;9(4):571-580.
https://doi.org/10.3233/JND-220801
[49] Mori-Yoshimura M, Kimura A, Tsuru A, Yajima H, Segawa K, Mizuno K, et al. Assessment of thrombocytopenia, sleep apnea, and cardiac involvement in GNE myopathy patients. Muscle Nerve 2022;65(3):284-290.
https://doi.org/10.1002/mus.27451
[50] Yoshioka W, Shimizu R, Takahashi Y, Oda Y, Yoshida S, Ishihara N, et al. Extra-muscular manifestations in GNE myopathy patients: A nationwide repository questionnaire survey in Japan. Clin Neurol Neurosurg 2022;212(107057.
https://doi.org/10.1016/j.clineuro.2021.107057
[51] Ranta-Aho J, Olive M, Vandroux M, Roticiani G, Dominguez C, Johari M, et al. Mutation update for the ACTN2 gene. Hum Mutat 2022;43(12):1745-1756.
https://doi.org/10.1002/humu.24470
[52] Harazi A, Becker-Cohen M, Zer H, Moshel O, Hinderlich S, Mitrani-Rosenbaum S. The Interaction of UDP-N-Acetylglucosamine 2-Epimerase/N-Acetylmannosamine Kinase (GNE) and Alpha-Actinin 2 Is Altered in GNE Myopathy M743T Mutant. Mol Neurobiol 2017;54(4):2928-2938.
https://doi.org/10.1007/s12035-016-9862-x
[53] Celeste FV, Vilboux T, Ciccone C, de Dios JK, Malicdan MC, Leoyklang P, et al. Mutation update for GNE gene variants associated with GNE myopathy. Hum Mutat 2014;35(8):915-26.
https://doi.org/10.1002/humu.22583
[54] Guo X, Zhao Z, Shen H, Bing Q, Li N, Chen J, et al. Gene analysis and clinical features of 22 GNE myopathy patients. Neurol Sci 2022;43(8):5049-5056.
https://doi.org/10.1007/s10072-022-06023-w
[55] Jiao K, Zhang J, Li Q, Lv X, Yu Y, Zhu B, et al. Novel variants and genotype-phenotype correlation in a multicentre cohort of GNE myopathy in China. J Med Genet 2024;61(11):1053-1061.
https://doi.org/10.1136/jmg-2024-110149

Figure 1: Axial T1-weighted MRI of thighs (A, B and C) and legs (D) in patient number 22 with advanced stage of disease. A, B, and C) The posterior and medial compartments of the thigh show severe fatty-fibrous infiltration with semitendinosus, biceps femoris brevis, sartorius, and gracilis totally replaced by fatty-fibrous tissue. The anterior compartment of the thigh is severely affected medially with rectus femoris and vastus intermedius almost totally replaced, while the vastus lateralis remains relatively spared. **D)** The fatty-fibrous infiltration of the leg muscles is diffuse and extremely severe with gastrocnemius (arrowhead) almost totally replaced.
Abbreviations: VL, vastus lateralis; VI, vastus intermedius; VM, vastus medialis, RF, rectus femoris; SA, sartorius; GR, gracilis; ST, semitendinosus; SM, semimembranosus; BFL, biceps femoris long head; BFB, biceps femoris short head.

Figure 2: *GNE* Schematic representation and variants predicted structure. A) Upper: *GNE* amino acids residues and its evolutionary conserved domains, with the alignment showing comparison across several vertebrates. Middle: Schematic representation of the *GNE* structure showing the location of the variants in the UDP-GIcNAc 2-Epimerase and ManNAc Kinase domains. **B)** AlphaFold2 *GNE* novel variants predicted structure. Squares contain the details of the changed amino acid.

Table 1: Clinical features of patient carrying biallelic *GNE* variants, included in this study.
M=Male, F=Female,

Table 2: List of identified variants found in our patient cohort.

Table 3: Variant classification and application of American College of Medical Genetics (ACMG) guidelines for variant interpretation to previously unreported variants found in the patient cohort.


VI
VL
A
B
RF
VM
VI
SA
GR
VL
BFB
BFL
SM
ST
C
D

A

	p.G355R	p.A679T	p.I709T	p.V727G	p.V744I
Homo sapiens	VINLGTRQIGRETGE	I LRTAGTALGLGVV	LASHY I HIVKDVI	LSSVQDVDVVVSDL	PALLGAASMVLDYTT
Mus musculus	VINLGTRQIGRETGE	I LRTAGTALGLGVV	LASHY I HIVKDVI	LSSVQDVDVVVSDL	PALLGAASMVLDYTT
Bos taurus	VINLGTRQIGRETGE	I LRTAGTALGLGVV	LASHY I HTVKDVI	LSSVQDVDVVVSDL	PALLGAASMVLDYTT
Gallus gallus	VINLGTRQTGRETGE	I LRTAGTALGLGVV	LASHYVNAVKDVI	LSSVKTVDVVVSNL	PALLGAAS LVLDYTT
Xenopus tropicalis	VINLGTRQTGRETGE	I LKTAGTALGI V I	LANQYVNVVKDVI	LASIQNVD VVVSSL	PALLGAASMVLDYTT
Danio rerio	VINLGTRQTGRETGE	VLHTAGTALGLGI V	LAVHYETPVRQVI	LLTAQGTK VMVSDL	PALLGAASMVLDYTT

B



	Variants							Muscle weakness					MRI			
Proband	Allele 1		Allele 2		Zygosity	Sex	Age range	Age of onset	Initial symptom	Latest assessment	Cardiac symptoms	Ambulation	Respiratory involvment (FVC)	Severly affected	Mildly affected	Unaffected	Muscle biopsy: rimmed vacuoles?
1	c.1618C>T	p.H540Y	c.1618C>T	p.H540Y	Hom.	M	60-65	20-25	Lower limb weakness	Hands, feet, upper and lower leg, forearm and upper arm, neck	*Not assessed*	Ambulant with 2 canes	106%	Tibialis anterior, gastrocnemius, soleus, adductors, harmstrings , thenar, hypothenar, and psoas muscles	Deltoids, pectoralis	Quadriceps, gluteı	Yes
2	c.922C>T	p.R308C	c.1850G>A	p.C617Y	Compound het.	F	70-75	50-55	Lower limb weakness (foot drop)	Upper and lower leg, neck	No	Ambulatory	110%	Tibialis anterior	Gastrocnemius, semitendinosus	Quadriceps, gluteı	No
3	c.268T>C	p.R90*	c.2086G>A	p.V696M	Compound het.	F	30-35	20-25	Lower limb weakness	Hands, feet, lower leg, upper arm, upper leg, paravertebral, neck, facial	No	No, loss at 25-30	73%	Tibialis anterior, gastrocnemius, peroneus longus, biceps femoris	None		Yes
4	c.986T>C	p.I329T	c.1618C>T	p.H540Y	Compound het.	M	60-65	40-45	Lower limb pain, difficulty climbing stairs	Lower leg, upper leg, paravertebral	No	Ambulatory	132%	Adductor, gluteus, trapezus, paravertebral muscles	Solear, vastus medialus, tibialis anterior	Quadriceps	Yes
5	c.537T>G	p.H179Q	c.922C>T	p.R308C	Compound het.	F	40-45	20-25	Difficulty walking on heels, limping	Lower leg	No	Ambulatory	122%	Tibialis anterior, gastrocnemius, soleus	Peroneus longus	Quadriceps	Yes
6	c.2180T>G	p.V727G	c.2230G>A	p.V744I	Compound het.	F	90-95	15-20	Lower limb weakness (foot drop)	Upper and lower leg, paravertebral, neck, facial	No	Ambulatory	*Not assessed*	Tibialis anterior, gastrocnemius, adductor, gluteus medius, biceps femoris	None	Quadriceps	Inconclusive
7	c.2126T>C	p.I709T	c.2086G>A	p.V696M	Compound het.	M	50-55	30-35	Right lower limb weakness (foot drop), ankle sprains	Lower leg, paravertebral, facial	No	Ambulatory	96%	None	Tibialis anterior, gastrocnemius	Quadriceps	Yes
8	c.986T>C	p.I329T	c.185 3T>C	p.I618T	Compound het.	M	30-35	15-20	Difficulty rising on toes	Hands, upper and lower leg, neck	No	Ambulatory	92%	Soleus	Gastrocnemius, tibialis anteror, biceps femoris, adductor	Quadriceps	Yes
9	c.922C>T	p.R308C	c.1850G>A	p.C617Y	Compound het.	F	50-55	35-40	Lower limb weakness (foot drop), ankle spains, falls	Hands, upper and lower leg, neck, facial	Mild aortic and mitral insufficiency	Ambulatory	113%	Tibialis anterior, biceps femoris	Gastrocnemius, adductor	Quadriceps	Yes
10	c.398T>C	p.L133P	c.2179G>A	p.V727M	Compound het.	M	30-35	25-30	Unilateral lower limb weakness	Hands, upper and lower leg	No	Ambulatory	*Not assessed*	Lower and upper leg	Gastrocnemius, tibialis anterior, bicep femoris, adductor	Quadriceps	Yes
11	c.2035G>A	p.A679T	c.2035G>A	p.A679T	Hom.	F	40-45	25-30	Lower limb weakness (foot drop)	Hands, feet, forearm, lower leg, upper arm, upper leg, paravertebral, neck, facia	Unspecific repolarization issues	No, loss at 30-35	75%	None	Diffuse	Quadriceps	Yes
12	c.922C>T	p.R308C	c.1892C>T	p.A631V	Compound het.	F	65-70	35-40	Hallux weakness	Upper and lower leg, paravertebral, neck	No	No, loss at 50-55	13% (not clear)	None	None		Yes
13	c.79C>T	p.R27*	c.1063G>A	p.G355R	Compound het.	M	75-80	40-45	Distal lower limb weakness	Hands, feet, forearm, lower leg	Hypertrophic cardiomyopathy	Ambulatory	No	*Not assessed*			*Not assessed*
14	c.829C>T	p.R277W	c.829C>T	p.R277W	Hom.	F	45-50	35-40	Lower limb weakness	Lower leg, feet, paravertebral, neck	No	Ambulatory	No	Anterior leg and posterior thigh	None	Quadriceps	Yes
15	c.2228T>C	p.M743T	c.2228T>C	p.M743T	Hom.	F	35-40	30-35	Fatigue	Hands, feet, lower leg, forearm, upper arm, paravertebral, neck	No	Ambulatory	No	Anterior leg and posterior thigh	Quadriceps		Yes
16	c.1649A>G	p.N550S	c.1649A>G	p.N550S	Hom.	M	35-40	25-30	Difficulty climbing stairs	Hands, feet, forearm, lower leg, upper arm, upper leg, paravertebral, neck, facia	No	Ambulatory	No	Anterior leg and posterior thigh	Quadriceps		Yes
17	c.185 3T>C	p.I618T	c.185 3T>C	p.I618T	Hom.	M	Unk	30-35	Steppage gait, anterior tibial weakness	Compatible with distal myopathy	*Not assessed*			*Not assessed*			Yes
18	c.185 3T>C	p.I618T	c.185 3T>C	p.I618T	Hom.	M	25-30	20-25	Distal lower limb weakness	Hands, feet, lower leg, upper leg	*Not assessed*	Ambulatory	*Not assessed*	Lower legs, posterior thigh	None	Quadriceps	No
19	c.705G>A	p.W235*	c.1096C>T	p.R366W	Compound het.	M	Unk	30-35	Tibial anterior muscle weakness	Distal muscle weakness	No			*Not assessed*			*Not assessed*
20	c.976G>A	p.G326S	c.2179G>A	p.V727M	Compound het.	M	25-30	15-20	Lower leg weakness	Hands, arms, upper and lower leg	Hypertensive cardiopathy	No, loss at 25-30	Moderate restrictive ventilatory defi	*Not assessed*			*Not assessed*

Variant			Protein				
Genomic (hg38)	**cDNA**	**Predicted effect**	**Domain**	**gnomAD (v4.1.0) Popmax Frequency**	**AlphaMissense**	**SpliceAI delta score, highest**	**Reference**
g.36249370G>A	c.79C>T	p.R27*	NA	0.00001099 (South Asian)	*Not assessed*	0.01	Nallamilli et al., 2018
g.36246472G>A	c.268C>T	p.R90*	NA	0.00001667 (Admixed American)	*Not assessed*	0.1	Cerino et al., 2015; Chakravorty et al., 2020
g.36246342A>G	c.398T>C	p.L133P	UDP-GlcNAc 2-Epimerase	0.0001201 (African/African American)	0.99	0.01	Nallamilli et al., 2018
g.36246203A>C	c.537T>G	p.H179Q	UDP-GlcNAc 2-Epimerase	Not found	0.9933	0.01	Cerino et al., 2015
g.36246035C>T	c.705G>A	p.W235*	NA	0.000003393 (European, non-Finnish)	*Not assessed*	0.05	Saechao et al., 2010
g.36236865G>A	c.829C>T	p.R277W	UDP-GlcNAc 2-Epimerase	0.00003333 (Admixed American)	0.2557	0	Darvish et al., 2002; Sparks et al., 2005; Stober et al., 2010; ; Mori-Yoshimura et al., 2012; Chamova et al., 2015; Pogoryelova et al., 2018; Guo et al., 2022
g.36234073G>A	c.922C>T	p.R308C	UDP-GlcNAc 2-Epimerase	0.0001650 (Middle Eastern)	0.1191	0	Behin et al., 2008; Mori-Yoshimura et al. 2012; Chaouch et al., 2019
g.36234019C>T	c.976G>A	p.G326S	UDP-GlcNAc 2-Epimerase	Not found	0.3026	0	Jones et al., 2013
g.36234009A>G	c.986T>C	p.I329T	UDP-GlcNAc 2-Epimerase	0.000001695 (European, non-Finnish)	0.6741	0	Saechao et al., 2010; Pogoryelova et al 2018; Chakravorty et al., 2020
g.36233932C>T	c.1063G>A	p.G355R	UDP-GlcNAc 2-Epimerase	Not found	0.8637	0	NA
g.36229088G>A	c.1096C>T	p.R366W	UDP-GlcNAc 2-Epimerase	0.00004461 (East Asian)	0.4625	0.01	Fisher et al., 2006; Saechao et al., 2010
g.36222885G>A	c.1618C>T	p.H540Y	ManNAc Kinase	0.00006682 (East Asian)	0.2101	0.2	Celeste et al., 2014; Zhao et al., 2015; Pogoryelova et al., 2018
g.36222854T>C	c.1649A>G	p.N550S	ManNAc Kinase	0.00000008475 (European, non-Finnish)	0.7143	0.07	Broccolini et al., 2004; Pogoryelova et al., 2018
g.36219897C>T	c.1850G>A	p.C617Y	ManNAc Kinase	0.00001098 (South Asian)	0.989	0.36	Cerino et al., 2015
g.36219894A>G	c.1853T>C	p.I618T	ManNAc Kinase	0.0001427 (South Asian)	0.4994	0.05	Eisenberg et al., 2002; Krause et al., 2007; Grandis et al., 2010; Li et al., 2011; Chamova et al., 2015; Papadimas et al., 2016; Pogoryelova et al., 2018; Chaouch et al., 2019; Chakravorty et al., 2020; Khadilkar et al., 2022
g.36219855G>A	c.1892C>T	p.A631V	ManNAc Kinase	Not found	0.7021	0.97	Tomimitsu et al., 2002; Vasconcelos et al 2002
g.36217592C>T	c.2035G>A	p.A679T	ManNAc Kinase	Not found	0.5327	0.01	NA
g.36217541C>T	c.2086G>A	p.V696M	ManNAc Kinase	Not found	0.5227	0	Nallamilli et al., 2018
g.36217501A>G	c.2126T>C	p.I709T	ManNAc Kinase	0.000002543 (European, non-Finnish)	0.0811	0	NA
g.36217448C>T	c.2179G>A	p.V727M	ManNAc Kinase	0.01241 (South Asian)	0.3065	0	Eisenberg et al., 2001; Huizing et al., 2004; Liewluck et al., 2006; Saechao et al., 2010; Voermans et al., 2010; Boyden et al., 2011; Nalini et al., 2013; No et al., 2013Tanboon et al., 2014; Huizing et al 2014; Garland et al., 2017; Zhu et al., 2017; Pogoryelova et al 2018;Chaouch et al. 2019; Chakravorty et al 2020; Torchia et al. 2021; Khadilkar et al., 2022
g.36217447A>C	c.2180T>G	p.V727G	ManNAc Kinase	Not found	0.7938	0.01	NA
g.36217399A>G	c.2228T>C	p.M743T	ManNAc Kinase	0.002630 (Middle Eastern)	0.7145	0	Eisenberg et al., 2001; Darvish et al., 2002; Broccolini et al., 2002; Tomimitsu et al., 2004; Amouri et al., 2004; Krause et al., 2007; Grandis et al., 2010; Mori-Yoshimura et al., 2012; Huizing et al., 2014; Haghighi et al., 2016; Pogoryelova et al 2018; Torchia et al., 2021
g.36217397C>T	c.2230G>A	p.V744I	ManNAc Kinase	Not found	0.2488	0	NA

			ACMG criteria										
Novel variants		Other allele	**PVS1**	**PP2**	**PP3**	**PP5**	**PP4**	**PM1**	**PM2**	**PM3**	**PM5**	**BP4**	**Classification**
c.1063G>A	**p.G355R**	p.R27* (Pathogenic)			Supporting		Supporting	Supporting	Supporting	Moderate	Supporting		Likely pathogenic
c.2035G>A	**p.A679T**	Homozygous					Supporting	Supporting	Supporting	Supporting	Supporting		VUS
c.2126T>C	**p.I709T**	p.V696M (Likely pathogenic)					Supporting	Supporting	Supporting	Moderate		Moderate	VUS
c.2180T>G	**p.V727G**	p.V744I (VUS)			Supporting		Supporting	Supporting	Supporting		Moderate		Likely pathogenic
c.2230G>A	**p.V744I**	p.V727G (Likely pathogenic)					Supporting	Supporting	Supporting	Moderate			VUS